- Thinly traded nano cap Aegerion Pharmaceuticals (AEGR) jumps 36% after hours on robust volume in response to its announcement that the Japanese Ministry of Health, Labor and Welfare has approved JUXTAPID (lomitapide) for the treatment of homozygous familial hypercholesterolemia (HoFH), the most severe form of abnormally high cholesterol.
- The approval is finally some good news for the company. Shares had lost over 95% of their value since early 2015 before rallying recently. Last quarter, the company pulled JUXTAPID from Europe and certain other markets due to lack of sales. In July, it cut 13% of its workforce in order to trim operating expenses.